STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] PETMED EXPRESS INC Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

PetMed Express reported receiving a Nasdaq notice on November 12, 2025 for failing to timely file its Quarterly Reports on Form 10‑Q for the periods ended June 30, 2025 (Q1) and September 30, 2025 (Q2), in addition to a prior delinquent Form 10‑K for the year ended March 31, 2025. The notice requires an updated compliance plan by November 28, 2025, and states any staff exception, if granted, will be limited to a maximum of 180 days from the initial delinquency, or December 29, 2025.

The company said the notice has no immediate effect on its Nasdaq listing and it intends to complete and file the Q1 10‑Q and Q2 10‑Q as promptly as possible. Separately, PetMed furnished a press release announcing preliminary, unaudited estimated revenues for the three‑ and nine‑month periods ended September 30, 2025; that information was furnished, not filed, under Item 2.02.

Positive
  • None.
Negative
  • Nasdaq noncompliance notice: update plan due Nov 28, 2025; any exception limited to Dec 29, 2025

Insights

Nasdaq deficiency notice adds firm deadlines; listing unaffected for now.

PetMed Express disclosed a Nasdaq notice tied to delayed Q1 and Q2 10‑Q filings, following an earlier 10‑K delinquency. Nasdaq requires an updated compliance plan by November 28, 2025, and limits any exception period to December 29, 2025.

The notice states there is no immediate effect on the listing. Actual outcome hinges on timely filings and Nasdaq’s review. The company indicates it is working to complete both 10‑Qs, but timing beyond these dates isn’t provided in the excerpt.

Key milestones are the plan update due November 28, 2025 and the outer exception limit on December 29, 2025. Subsequent disclosures will clarify filing status and compliance.

0001040130FALSE00010401302025-11-122025-11-120001040130us-gaap:CommonStockMember2025-11-122025-11-120001040130us-gaap:PreferredStockMember2025-11-122025-11-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 12, 2025
PetMed Express, Inc.
(Exact name of registrant as specified in its charter)
Florida
000-28827
65-0680967
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
420 South Congress Avenue, Delray Beach, Florida 33445
(Address of principal executive offices) (Zip Code)
(561526-4444
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $.001 per share
PETS
NASDAQ
Preferred Stock Purchase RightsN/ANASDAQ
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. o



Item 2.02 Results of Operations and Financial Condition.

On November 13, 2025, PetMed Express, Inc. (the “Company”) issued a press release announcing preliminary estimated revenues for the three- and nine-month periods ended September 30, 2025. These preliminary estimated revenues are unaudited, based on currently available information and do not present all necessary information for a complete understanding of the Company’s financial condition as of September 30, 2025, or its results of operations for the three- and nine-month periods ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.
The information furnished in this Item 2.02 on this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, regardless of any general incorporation language in such filing.

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On November 12, 2025, the Company received an expected notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), which indicated that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 (the “Q2 10-Q”), in addition to its continued delinquency in filing its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 (the “Q1 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires Nasdaq-listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission (the “SEC”). The Notice further states that, because the Company was delinquent in filing its Form 10-K for the fiscal year ended March 31, 2025 (the “Initial Delinquent Filing”) and remains delinquent in filing the Q1 10-Q, any Nasdaq Staff exception to allow the Company to regain compliance, if granted, will be limited to a maximum of 180 calendar days from the due date of the Initial Delinquent Filing, or December 29, 2025.

The Notice states that, as a result of the additional delinquency, the Company must submit, by November 28, 2025, an update to its original plan to regain compliance with respect to the filing requirement. The Company previously submitted its original plan to regain compliance to Nasdaq on September 2, 2025, and the Company intends to timely update Nasdaq with respect to the plan by November 28, 2025.

The Notice has no immediate effect on the listing of the Company’s common stock on Nasdaq.

While the Company can provide no assurances as to timing, the Company continues to work diligently to complete its Q1 10-Q and Q2 10-Q and intends to file them as promptly as possible to regain compliance with the Listing Rule.


Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

Exhibit No.
Description
99.1
Press release.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)



Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements. Words such as “may,” “could,” “expect,” “project,” “outlook,” “strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “strive,” “goal,” “continue,” “likely,” “will,” “would” and other similar words and expressions are intended to signify forward-looking statements. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain and are subject to various risks and uncertainties,
2


including: the Company’s ability to complete the filing of its Q1 10-Q and Q2 10-Q within the anticipated time period; the Company’s ability to regain compliance with Nasdaq listing standards; and the time and effort required to complete and file the Company’s financial statements and Form 10-Qs for its fiscal quarters ending June 30, 2025, and September 30, 2025. The Company’s future results may also be impacted by other risk factors listed from time to time in the Company’s filings with the SEC, including, but not limited to, the Company's Annual Report on Form 10-K for the year ended March 31, 2025, as well as other subsequent filings on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Current Report on Form 8-K and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.
3


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 13, 2025
PETMED EXPRESS, INC.
By:/s/ Douglas Krulik
Name:Douglas Krulik
Title:Chief Accounting Officer, Interim Principal Financial Officer and Treasurer
4

FAQ

What did PetMed Express (PETS) disclose in this 8-K?

The company received a Nasdaq notice due to delayed Q1 and Q2 10‑Q filings, with an update plan due by November 28, 2025.

Does the Nasdaq notice immediately affect PETS’ listing?

No. The notice states there is no immediate effect on the company’s Nasdaq listing.

What are the key deadlines mentioned for PETS’ compliance?

An updated plan is due November 28, 2025, and any exception, if granted, runs only until December 29, 2025.

Which SEC reports are outstanding for PetMed Express (PETS)?

The Form 10‑Q for June 30, 2025 (Q1) and the Form 10‑Q for September 30, 2025 (Q2), following an earlier delinquent Form 10‑K.

What financial information did PETS furnish alongside the notice?

A press release with preliminary, unaudited estimated revenues for the three‑ and nine‑month periods ended September 30, 2025.

Are the preliminary revenues considered filed with the SEC?

No. They were furnished, not filed, and are not subject to Section 18 liabilities.
Petmed Express Inc

NASDAQ:PETS

PETS Rankings

PETS Latest News

PETS Latest SEC Filings

PETS Stock Data

41.09M
14.39M
30.82%
37.94%
9.44%
Pharmaceutical Retailers
Retail-drug Stores and Proprietary Stores
Link
United States
DELRAY BEACH